Novo Nordisk Archives

News and Trends 21 Sep 2022

Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research

The Novo Nordisk Foundation has awarded a grant of $200 million to establish the first full-scale quantum computer for the development of new medicines. The computer will also provide new insights into climate change and the green transition, which is not possible with classical computers today. The computer could be located in a data center, […]

September 21, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

More companies enter BioInnovation Institute Venture Lab program

Nine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BioInnovation Institute is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – […]

September 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 6 Jun 2022

Report shows growth of life sciences sector in eastern Denmark

A new report on the Danish contribution to the Medicon Valley has been published. The report, Life Science in Eastern Denmark – The Danish Part of Medicon Valley is a survey of companies in the sector. Medicon Valley spans the Danish region of Zealand and the Capital Region, and the Skåne region of southern Sweden. […]

June 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2022

Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments

The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […]

January 17, 2022 - 3 minutesmins - By Dan Samorodnitsky

News and Trends 1 Oct 2021

Novo Nordisk Foundation Pumps €85M into Carbon Capture Research

As pressure mounts to tackle climate change, the Danish Novo Nordisk Foundation has granted €84.7M to the world’s first research institution dedicated to capturing carbon dioxide from the air and harnessing the gas as a raw material. The new Novo Nordisk Foundation CO2 Research Center has the mission to efficiently capture, store, and recycle the […]

October 1, 2021 - 6 minutesmins - By Anita Chakraverty

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 15 Jun 2020

Novo Nordisk Foundation Commits €100M Grant to Developing Green Tech

The Novo Nordisk Foundation has awarded a five-year grant of €100M to the DTU Biosustain research center near Copenhagen to support the development of sustainable green technology. DTU Biosustain was founded in 2011 and forms part of the Danish Technical University. The Novo Nordisk Foundation, which is one of the largest charitable foundations in the […]

June 15, 2020 - 3 minutesmins - By Helen Albert

News and Trends 13 May 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]

May 13, 2020 - 4 minutesmins - By Helen Albert

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

More News! 9 Oct 2019

Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing

The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […]

October 9, 2019 - 1 minutemin - By Jonathan Smith

novo nordisk type 2 diabetes semaglutide

News and Trends 23 Sep 2019

FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug

The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […]

September 23, 2019 - 2 minutesmins - By Jonathan Smith

novo nordisk staten fat hypertriglyceridemia cardiovascular disease

News and Trends 17 Dec 2018

Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease

Novo Nordisk and the Dutch company Staten Biotechnology will partner to develop a treatment to remove excess fatty molecules called triglycerides from the blood, high levels of which increase a person’s risk for cardiovascular disease. Novo has agreed to pay up to €430M for the worldwide rights to Staten’s candidate drug, as well as the exclusive […]

December 17, 2018 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us